Trial Profile
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2022
Price :
$35
*
At a glance
- Drugs Sapanisertib (Primary) ; Serabelisib (Primary) ; Everolimus
- Indications Carcinoma; Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 09 Dec 2022 Results assessing the efficacy and safety of single-agent sapanisertib and sapanisertib plus TAK-117, vs. everolimus in patients with advanced clear cell renal cell carcinoma , published in the Oncologist
- 04 Jun 2020 Status changed from active, no longer recruiting to completed.
- 24 May 2020 This trial has been completed in Poland, according to European Clinical Trials Database.